Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Lupin receives US FDA approval for raltegravir tablets USP, 600 mg: Our Bureau, Mumbai Thursday, May 8, 2025, 17:25 Hrs [IST] Global pharma major Lupin Limited (Lupin) announced t ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

As part of the 10th Mediterranean Neuroscience Society Conference, we are excited to present this new collection of articles ...

Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Research and Development (R&D) Expenses: R&D expenses decreased to $5.8 million for the three months ended March 31, 2025, ...

High-ranking OpenAI employees have met with the FDA multiple times in recent weeks to discuss AI and a project called cderGPT ...